MFSD2A and neoplasm: Loss of MFSD2A promotes metastatic tumor growth and survival in the brain microenvironment by altering DHA transport and metabolism, revealing that restoring DHA and/or its metabolites to the tumor microenvironment may be an effective treatment strategy for patients with metastatic brain cancer.